Hubbry Logo
GyromitrinGyromitrinMain
Open search
Gyromitrin
Community hub
Gyromitrin
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Gyromitrin
Gyromitrin
Gyromitrin
View on Wikipedia
from Wikipedia
Gyromitrin
Wireframe model of gyromitrin
Wireframe model of gyromitrin
Ball and stick model of gyromitrin
Ball and stick model of gyromitrin
Names
IUPAC name
N′-Ethylidene-N-methylformohydrazide
Other names
Acetaldehyde methylformylhydrazone
Formic acid 2-ethylidene-1-methylhydrazide
Identifiers
3D model (JSmol)
1922396
ChEBI
ChemSpider
KEGG
MeSH Gyromitrin
UNII
  • InChI=1S/C4H8N2O/c1-3-5-6(2)4-7/h3-4H,1-2H3
    Key: IMAGWKUTFZRWSB-UHFFFAOYSA-N
  • CC=NN(C)C=O
Properties
C4H8N2O
Molar mass 100.121 g·mol−1
Boiling point 143 °C (289 °F; 416 K)
Hazards
Occupational safety and health (OHS/OSH):
Main hazards
 Toxic
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Gyromitrin is a toxin and carcinogen present in several members of the fungal genus Gyromitra, like G. esculenta. Its formula is C4H8N2O. It is unstable and is easily hydrolyzed to the toxic compound monomethylhydrazine CH3NHNH2. Monomethylhydrazine acts on the central nervous system and interferes with the normal use and function of vitamin B6. Poisoning results in nausea, stomach cramps, and diarrhea, while severe poisoning can result in convulsions, jaundice, or even coma or death. Exposure to monomethylhydrazine has been shown to be carcinogenic in small mammals.

History

[edit]

Poisonings related to consumption of the false morel Gyromitra esculenta, a highly regarded fungus eaten mainly in Finland and by some in parts of Europe and North America, had been reported for at least a hundred years. Experts speculated the reaction was more of an allergic one specific to the consumer, or a misidentification, rather than innate toxicity of the fungus, due to the wide range in effects seen. Some would suffer severely or perish while others exhibited no symptoms after eating similar amounts of mushrooms from the same dish. Yet others would be poisoned after previously eating the fungus for many years without ill-effects.[1] In 1885, Böhm and Külz described helvellic acid, an oily substance they believed to be responsible for the toxicity of the fungus.[2] The identity of the toxic constituents of Gyromitra species eluded researchers until 1968, when N-methyl-N-formylhydrazone was isolated by German scientists List and Luft and named gyromitrin. Each kilogram of fresh false morel had between 1.2 and 1.6 grams of the compound.[3][contradictory]

Mechanism of toxicity

[edit]
MMH (CH3NHNH2), a toxic metabolite

Gyromitrin is a volatile, water-soluble hydrazine compound that can be hydrolyzed in the body into monomethylhydrazine (MMH) through the intermediate N-methyl-N-formylhydrazine.[4]

Gyromitrin mechanism of action

Other N-methyl-N-formylhydrazone derivatives have been isolated in subsequent research, although they are present in smaller amounts. These other compounds would also produce monomethylhydrazine when hydrolyzed, although it remains unclear how much each contributes to the false morel's toxicity.[5]

The toxins react with pyridoxal 5-phosphate—the activated form of pyridoxine—and form a hydrazone. This reduces production of the neurotransmitter GABA via decreased activity of glutamic acid decarboxylase,[6] which gives rise to the neurological symptoms. MMH also causes oxidative stress leading to methemoglobinemia.[7] Additionally during the metabolism of MMH, N-methyl-N-formylhydrazine is produced; this then undergoes cytochrome P450 regulated oxidative metabolism which via reactive nitrosamide intermediates leads to formation of methyl radicals which lead to liver necrosis.[8][9] Inhibition of diamine oxidase (histaminase) elevates histamine levels, resulting in headaches, nausea, vomiting, and abdominal pain.[10] Giving pyridoxine to rats poisoned with gyromitrin inhibited seizures, but did not prevent liver damage.

The toxicity of gyromitrin varies greatly according to the animal species being tested. Tests of administering gyromitrin to mice to observe the correlation between the formation of MMH and stomach pH have been performed. Higher levels of formed MMH were observed in the stomachs of the mice than were observed in control tests under less acidic conditions. The conclusions drawn were that the formation of MMH in a stomach is likely a result of acid hydrolysis of gyromitrin rather than enzymatic metabolism.[4] Based on this animal experimentation, it is reasonable to infer that a more acidic stomach environment would transform more gyromitrin into MMH, independent of the species in which the reaction is occurring.[4]

The median lethal dose (LD50) is 244 mg/kg in mice, 50–70 mg/kg in rabbits, and 30–50 mg/kg in humans.[11] The toxicity is largely due to the MMH that is created; about 35% of ingested gyromitrin is transformed to MMH.[12] Based on this conversion, the LD50 of MMH in humans has been estimated to be 1.6–4.8 mg/kg in children, and 4.8–8 mg/kg in adults.[11]

Occurrence and removal

[edit]
Gyromitra esculenta

Several Gyromitra species are traditionally considered very good edibles and several steps are available to remove gyromitrin from these mushrooms and allow their consumption. For North America, the toxin has been reliably reported from the species G. esculenta, G. gigas, and G. fastigiata. Species in which gyromitrin's presence is suspected, but not proven, include G. californica, G. caroliniana, G. korfii, and G. sphaerospora, in addition to Disciotis venosa and Sarcosphaera coronaria. The possible presence of the toxin renders these species "suspected, dangerous, or not recommended" for consumption.[13]

Gyromitrin content can differ greatly in different populations of the same species. For example, G. esculenta collected from Europe is "almost uniformly toxic", compared to rarer reports of toxicity from specimens collected from the US west of the Rocky Mountains.[14] A 1985 study reported that the stems of G. esculenta contained twice as much gyromitrin as the cap, and that mushrooms collected at higher altitudes contained less of the toxin than those collected at lower altitudes.[11]

The gyromitrin content in false morels has been reported to be in the range of 40–732 milligrams of gyromitrin per kilogram of mushrooms (wet weight).[15] Gyromitrin is volatile and water soluble, and can be mostly removed from the mushrooms by cutting them to small pieces and repeatedly boiling them in copious amounts of water under good ventilation. Prolonged periods of air drying also reduces levels of the toxin.[15] In the US, there are typically between 30 and 100 cases[how often?] of gyromitrin poisoning requiring medical attention. The mortality rate for cases worldwide is about 10%.[16]

Detection

[edit]

The early methods developed for the determination of gyromitrin concentration in mushroom tissue were based on thin-layer chromatography and spectrofluorometry, or the electrochemical oxidation of hydrazine. These methods require large amounts of sample, are labor-intensive and unspecific. A 2006 study reported an analytical method based on gas chromatography-mass spectrometry with detection levels at the parts per billion level. The method, which involves acid hydrolysis of gyromitrin followed by derivatization with pentafluorobenzoyl chloride, has a minimum detectable concentration equivalent to 0.3 microgram of gyromitrin per gram of dry matter.[15]

Identification

[edit]
Comparison of Gyromitra esculenta and a morel mushroom

When foraging for mushrooms in the wild, it is important to be cautious of ones that may not be safe to eat. Morel mushrooms are highly sought after; however, they can easily be confused with Gyromitra esculenta, also known as “false morels”. There are a few differing characteristics between the two species that can be used to avoid accidental poisoning. The cap of a real morel mushroom attaches directly to the stem, while the cap of a false morel grows around the stem. Real morel mushrooms are also hollow from top to bottom when cut in half, which varies from the filled nature of false morels. Finally, based on outward appearance, real morels are rather uniformly shaped and covered in pits that seem to fall inwards, whereas false morels are often considered more irregularly shaped with wavy ridges that seem to form outwards.[17]

Poisoning

[edit]

Symptoms

[edit]

The symptoms of poisoning are typically gastrointestinal and neurological.[18] Symptoms occur within 6–12 hours of consumption, although cases of more severe poisoning may present sooner—as little as 2 hours after ingestion. Initial symptoms are gastrointestinal, with sudden onset of nausea, vomiting, and watery diarrhea which may be bloodstained. Dehydration may develop if the vomiting or diarrhea is severe. Dizziness, lethargy, vertigo, tremor, ataxia, nystagmus, and headaches develop soon after;[18] fever often occurs, a distinctive feature which does not develop after poisoning by other types of mushrooms.[19] In most cases of poisoning, symptoms do not progress from these initial symptoms, and patients recover after 2–6 days of illness.[20]

In some cases there may be an asymptomatic phase following the initial symptoms which is then followed by more significant toxicity including kidney damage,[21] liver damage, and neurological dysfunction including seizures and coma.[7] These signs usually develop within 1–3 days in serious cases.[18] The patient develops jaundice and the liver and spleen become enlarged, in some cases blood sugar levels will rise (hyperglycemia) and then fall (hypoglycemia) and liver toxicity is seen. Additionally, intravascular hemolysis causes destruction of red blood cells resulting in increases in free hemoglobin and hemoglobinuria, which can lead to kidney toxicity or kidney failure. Methemoglobinemia may also occur in some cases. This is where higher than normal levels of methemoglobin—a form of hemoglobin that can not carry oxygen—are found in the blood. It causes the patient to become short of breath and cyanotic.[22] Cases of severe poisoning may progress to a terminal neurological phase, with delirium, muscle fasciculations and seizures, and mydriasis progressing to coma, circulatory collapse, and respiratory arrest.[23] Death may occur from five to seven days after consumption.[24]

Toxic effects from gyromitrin may also be accumulated from sub-acute and chronic exposure due to "professional handling"; symptoms include pharyngitis, bronchitis, and keratitis.[18]

Treatment

[edit]

Treatment is mainly supportive; gastric decontamination with activated charcoal may be beneficial if medical attention is sought within a few hours of consumption. However, symptoms often take longer than this to develop, and patients do not usually present for treatment until many hours after ingestion, thus limiting its effectiveness.[25] Patients with severe vomiting or diarrhea can be rehydrated with intravenous fluids.[20] Monitoring of biochemical parameters such as methemoglobin levels, electrolytes, liver and kidney function, urinalysis, and complete blood count is undertaken and any abnormalities are corrected. Dialysis can be used if kidney function is impaired or the kidneys are failing. Hemolysis may require a blood transfusion to replace the lost red blood cells, while methemoglobinemia is treated with intravenous methylene blue.[26]

Pyridoxine, also known as vitamin B6, can be used to counteract the inhibition by MMH on the pyridoxine-dependent step in the synthesis of the neurotransmitter GABA. Thus GABA synthesis can continue and symptoms are relieved.[27] Pyridoxine, which is only useful for the neurological symptoms and does not decrease hepatic toxicity,[9][28] is given at a dose of 25 mg/kg; this can be repeated up to a maximum total of 15 to 30 g daily if symptoms do not improve.[29] Benzodiazepines are given to control seizures; as they also modulate GABA receptors they may potentially increase the effect of pyridoxine. Additionally MMH inhibits the chemical transformation of folic acid into its active form, folinic acid, this can be treated by folinic acid given at 20–200 mg daily.[7]

Toxicity controversy

[edit]

Due to variances seen in the effects of consumption of the Gyromitra esculenta, there is some controversy surrounding its toxicity. Historically, there was some confusion over what was causing the symptoms to form after consuming the mushrooms. Over time, there were poisonings across Europe due to the consumption of Gyromitra mushrooms; however, the toxin causing the poisonings was unknown at that time. In 1793, mushroom poisonings that occurred in France were attributed to Morchella pleopus, and in 1885, the poisonings were said to be caused by “helvellic acid”. The identity of the toxin found in Gyromitra was not known until List and Luft of Germany were able to isolate and identify the structure of gyromitrin from these mushrooms in 1968.[30]

Gyromitrin may not be considered especially toxic, which may lead people to underestimate its poisonous qualities. In Poland, from 1953 to 1962, there were 138 documented poisonings, only two of which were fatal. Of 706 calls to the Swedish poison center regarding Gyromitra mushrooms between 1994 and 2002, there were no fatalities. In the United States from 2001 to 2011, 448 calls to poison centers involved gyromitrin. The North American Mycological Association (NAMA) reported on 27 cases over 30 years, none of which were fatal.[30] Although poisonings due to gyromitrin are not often fatal, it is still highly toxic to the liver.[31] Of those 27 analyzed cases, nine developed liver injury; there were also three instances of acute kidney injury.[30] As gyromitrin is not especially stable, most poisonings apparently occur from the consumption of the raw or insufficiently cooked "false morel" mushrooms.[31]

There are also possibly several strains of Gyromitra esculenta that vary from region to region and have differing levels of the toxin. For example, there is a less toxic variety that grows west of the Rockies in North America. The toxin may also diminish as the seasons change, as most exposures occur in the Spring.[30] This may help explain some conflicting reports on whether the fungus is edible or not.[31]

Carcinogenicity

[edit]

Monomethylhydrazine,[32] as well as its precursors methylformylhydrazine[33][34] and gyromitrin[35] and raw Gyromitra esculenta,[36] have been shown to be carcinogenic in experimental animals.[37][38] Although Gyromitra esculenta has not been observed to cause cancer in humans,[39] it is possible there is a carcinogenic risk for people who ingest these types of mushrooms.[33] Even small amounts may have a carcinogenic effect.[40] At least 11 different hydrazines have been isolated from Gyromitra esculenta, and it is not known if the potential carcinogens can be completely removed by parboiling.[41]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Gyromitrin

View on Grokipedia
from Grokipedia
Gyromitrin is a volatile, water-soluble (C₄H₈N₂O), chemically known as N-methyl-N-formyl, primarily produced by mushrooms in the genus , especially . This compound hydrolyzes in the acidic environment of the to N-methyl-N-formylhydrazine (MFH) and further metabolizes to (MMH), the primary toxic metabolite responsible for its effects. Found in concentrations ranging from 40–732 mg/kg in fresh mushrooms (or up to 11,237 mg/kg in dried samples of certain species like G. venenata), gyromitrin's presence varies by species, geographic location, and environmental factors, with lower or undetectable levels in some, such as G. gigas. Despite G. esculenta being historically considered edible in some cultures after , which significantly reduces the (with older studies reporting up to 99% removal, though a 2025 report indicates approximately 18% may remain after double ), raw or improperly prepared consumption leads to gyromitrin , a potentially fatal condition with an LD50 of 340 mg/kg in mice for gyromitrin itself and 33 mg/kg for MMH. The toxin's mechanism involves MMH inhibiting pyridoxal phosphokinase, depleting gamma-aminobutyric acid (GABA) in the , and generating free radicals that damage hepatocytes and nephrons, resulting in , , and ; gyromitrin is also potentially carcinogenic. Symptoms typically emerge in two phases: initial gastrointestinal effects (, , , ) within 5–12 hours, followed by delayed hepatic and renal injury, , seizures, and in severe cases, or death, though fatalities are rare with prompt treatment. Management of gyromitrin poisoning is supportive, including activated charcoal for , intravenous fluids for hydration, and () at 25 mg/kg to counteract GABA depletion and seizures, often combined with benzodiazepines if needed. and multiple water changes during cooking significantly reduce risk, but regulatory bodies like the FDA advise against consuming false morels due to inconsistent toxin levels and potential for misidentification with edible true morels (Morchella spp.). Recent studies have also explored links between chronic low-level exposure and neurodegenerative conditions like (), particularly in slow acetylators who metabolize MMH less efficiently via N-acetyltransferase-2 (NAT2).

Overview

Definition and Chemical Identity

Gyromitrin is a hydrazone toxin, chemically identified as the N-methyl-N-formylhydrazone of acetaldehyde (also known as N'-[(1Z)-ethylidene]-N-methylformohydrazide), primarily occurring in certain fungal species within the genus Gyromitra. This compound represents a key mycotoxin associated with these fungi, distinguishing it from other hydrazine derivatives through its specific structural motif involving a formyl group linked to a hydrazone. The molecular formula of gyromitrin is C₄H₈N₂O, and its molecular weight is 100.12 g/mol. It belongs to the class of N-alkylated s, organic compounds featuring a [hydrazone functional group](/page/Hydrazone /page/Functional_group) where the is substituted with an alkyl chain. In its pure form, gyromitrin is a colorless to pale yellow liquid that is odorless, unstable, and highly volatile, with a of approximately 143°C. It exhibits good in as a polar and is also soluble in organic solvents such as and , facilitating its extraction and analysis.

Sources and Distribution

Gyromitrin is primarily sourced from certain species within the fungal genus , with the highest concentrations occurring in Gyromitra esculenta, commonly known as the . Other species such as G. gigas and G. fastigiata contain lower levels of the toxin (0.05-0.74 mg/kg fresh weight), contributing to fewer reported incidents. These mushrooms produce gyromitrin as a through fungal metabolic pathways involving derivatives, though the exact biosynthetic genes remain unidentified. Concentrations of gyromitrin in G. esculenta exhibit considerable variability depending on factors such as geographic location, environmental conditions, and even within the same fruiting body, with higher levels often found in the caps compared to the stipes. Reported levels in fresh G. esculenta range from 40 to 732 mg/kg wet weight, while dried specimens can contain 500 to 3,000 mg/kg, highlighting the toxin's volatility and potential for accumulation during processing. In contrast, G. gigas and G. fastigiata typically show lower concentrations, sometimes as little as 0.05 to 0.74 mg/kg fresh weight, contributing to fewer reported incidents from these species. These gyromitrin-producing Gyromitra species are predominantly distributed across the , thriving in temperate regions of Europe—including Scandinavia (such as and ) and (such as and )—as well as (including , , and western Canada). Occurrences extend to parts of , though less frequently documented. The fungi favor sandy or acidic soils in coniferous forests, often near pines or aspens, and exhibit a distinct seasonal pattern, emerging in spring shortly after and persisting into early summer. This temporal and spatial distribution influences human exposure risks, particularly during foraging seasons in these ecosystems.

Chemical Properties

Structure and Stability

Gyromitrin possesses the molecular formula C₄H₈N₂O and is structured as the N-methyl-N-formylhydrazone of , featuring the key functional group CH₃CH=NN(CH₃)CHO, where the distal bears both a methyl and a formyl group. This configuration was definitively elucidated through isolation and synthesis efforts in the late . The central linkage (C=N) connects the acetaldehyde-derived moiety to the substituted , imparting the compound's reactivity profile. A defining characteristic of gyromitrin's structure is the labile N-N within the framework, which renders it susceptible to hydrolytic cleavage and distinguishes it from more stable nitrogen-containing heterocycles. This bond's weakness facilitates non-enzymatic breakdown, releasing and N-methyl-N-formylhydrazine under hydrolytic stress. Gyromitrin demonstrates chemical instability in protic media, undergoing spontaneous decomposition at , particularly accelerating in acidic or basic environments due to or nucleophilic attack on the N-N bond. It remains relatively stable in neutral aqueous solutions (e.g., pH 6.8) but hydrolyzes rapidly at low pH (e.g., pH 1.2), mimicking gastric conditions. In contrast, gyromitrin persists in dry fungal tissue, where lack of moisture inhibits , though volatility can lead to partial loss during prolonged drying. The moiety in gyromitrin is identifiable through distinctive spectroscopic signatures, including (IR) absorption bands around 1620–1580 cm⁻¹ for the C=N stretch and (NMR) signals such as the formyl proton at approximately 8.5 ppm and the N-methyl group at 3.2 ppm in ¹H NMR, alongside corresponding ¹³C NMR resonances for the carbon. These features, observed in synthetic and isolated samples, confirm the structural integrity and enable analytical detection.

Metabolism and Derivatives

Gyromitrin undergoes primary in the acidic environment of the , initially breaking down into N-methyl-N-formylhydrazine (MFH) and . This intermediate, MFH, is then further hydrolyzed or metabolized, primarily in the liver via enzymes, to yield (MMH) and (HCHO). The overall reaction can be represented as: Gyromitrin+H2O→N-methyl-N-formylhydrazine→MMH+HCHO\text{Gyromitrin} + \text{H}_2\text{O} \rightarrow \text{N-methyl-N-formylhydrazine} \rightarrow \text{MMH} + \text{HCHO} Following its formation, MMH is absorbed into the bloodstream and undergoes further metabolism, where it binds to and inhibits pyridoxal phosphokinase, thereby preventing the phosphorylation of vitamin B6 (pyridoxine) to its active form, pyridoxal 5'-phosphate. This inhibition disrupts vitamin B6-dependent enzymatic processes, notably the activity of glutamic acid decarboxylase, which leads to depletion of gamma-aminobutyric acid (GABA), an essential inhibitory neurotransmitter. Among gyromitrin's derivatives, MMH serves as the principal hepatotoxin and responsible for the compound's , while other hydrazines such as MFH occur in trace amounts and contribute minimally to the overall effects. The structural instability of gyromitrin facilitates this rapid in biological systems.

History

Discovery and Isolation

The of Gyromitra species was initially recognized in 18th- and 19th-century European reports of mushroom poisonings, with cases documented in as early as 1793, where symptoms were attributed to the fungus then classified as Morchella pleopus. In 1885, an extract from these mushrooms was isolated and termed "helvellic acid," which subsequent research identified as the precursor to the true toxin gyromitrin. During the 1950s, increased attention focused on poisonings, particularly in , where studies documented numerous incidents linked to consumption. For instance, Polish medical literature reported 138 cases between 1953 and 1962, including two fatalities, underscoring the variable severity and prompting investigations into the underlying toxic agents. These efforts linked the symptoms to derivatives, building on earlier observations of gastrointestinal and neurological effects. The isolation of gyromitrin occurred in 1968, when German chemists P. H. List and P. Luft purified N-methyl-N-formylhydrazone (acetaldehyde N-methyl-N-formylhydrazone) from G. esculenta specimens. They synthesized the compound and confirmed its role as the primary toxin, deriving the name "gyromitrin" from the fungal genus Gyromitra. This nomenclature was formalized in the early 1970s through additional biochemical validations. Further confirmation and structural details emerged in the 1970s, with spectroscopic analyses such as NMR and elucidating gyromitrin's instability and pathways. By the 1980s, advanced spectroscopic methods refined the understanding of its structure, solidifying its identification as a volatile, water-soluble present in concentrations of 50–300 mg/kg in fresh G. esculenta fruiting bodies.

Historical Incidents

Early records of gyromitrin poisoning date back to the late 18th and 19th centuries in Europe, where consumption of Gyromitra esculenta, known locally as "Lorchel" in German-speaking regions, often led to fatalities due to its resemblance to edible morels. For instance, poisonings were reported in France as early as 1793, with victims experiencing severe gastrointestinal distress and liver failure after mistaking the false morel for safe species. In Sweden, several lethal cases were documented in the late 19th century, highlighting the risks of raw or inadequately prepared mushrooms in traditional foraging practices. During the mid-20th century, outbreaks of gyromitrin poisoning were particularly notable in , where G. esculenta was traditionally consumed as a despite known hazards. In , between 1875 and 1988, at least four deaths were attributed to raw consumption, reflecting episodic epidemics tied to seasonal . Similarly, in , incidents in the prompted greater scrutiny of the mushroom's edibility. In the United States, cases emerged in the amid a surge in wild mushroom , particularly in the Midwest and , with reports of gastrointestinal and hepatic symptoms but no recorded fatalities. The cultural significance of G. esculenta in and persisted through the , with traditional preparation methods like repeated used to mitigate , yet risks remained due to variable toxin levels. This led to regulatory measures by the 1970s, including bans on commercial sale in and mandatory preparation warnings for sales in , aimed at reducing accidental poisonings. Mortality from gyromitrin poisoning was historically significant in severe, untreated European cases before the , primarily due to delayed recognition of symptoms and lack of targeted treatments; rates declined thereafter as identity was established and awareness grew.

Occurrence in Nature

Fungal Species Involved

, a toxic derivative, is primarily produced by certain species within the , particularly , which is known for containing the highest levels of the , ranging from 40–732 mg/kg in fresh fruiting bodies. This species is the most commonly implicated in gyromitrin poisonings due to its widespread consumption in some regions, despite its hazardous nature. Gyromitra venenata also produces high levels, up to 11,237 mg/kg in dried samples. In contrast, Gyromitra gigas exhibits lower and more variable gyromitrin concentrations, often undetectable in some samples, making it less toxic but still potentially dangerous depending on environmental and developmental factors. Other species, such as Gyromitra fastigiata and Gyromitra infula, also produce gyromitrin, though typically at moderate levels that can vary significantly between specimens and locations. Trace amounts of gyromitrin have been detected in some species of the related genus Helvella, including and Helvella lacunosa, but these are generally not considered significant sources of the toxin compared to Gyromitra species. The distribution of these fungi is predominantly in the , where they fruit in spring under coniferous or trees. Toxin levels in gyromitrin-producing fungi show notable variation influenced by the developmental of the fruiting body, with higher concentrations often found in younger specimens before maturation dilutes the through growth. Within the fruiting body, gyromitrin is more abundant in the caps than in the stipes, which can influence exposure risks during or preparation. This intraspecific and interstructural variability underscores the unpredictability of even within a single . Recent genomic studies have identified potential biosynthesis genes associated with gyromitrin production in , including clusters involved in metabolism, as revealed through post-2010 sequencing efforts that highlight evolutionary adaptations in toxin production pathways. These findings provide insights into the genetic basis for gyromitrin accumulation, aiding in distinguishing toxic from non-toxic lineages within the fungi.

Environmental Factors

The abundance and gyromitrin content in Gyromitra esculenta, a primary fungal source of the toxin, are shaped by seasonal cycles that align with temperate climate dynamics. Fruiting bodies typically emerge in spring, from March to May in European and North American regions, triggered by post-thaw soil warming and rising temperatures that facilitate mycelial growth and sporocarp development. This timing coincides with early-season moisture availability following winter dormancy, promoting higher yields in undisturbed habitats. Habitat preferences further dictate gyromitrin production and fungal distribution, with G. esculenta favoring acidic, sandy soils rich in , often in coniferous forests dominated by pines. These conditions, typically found in well-drained, duff-covered ground near tree bases, support saprobic and potential mycorrhizal associations that enhance uptake and biosynthesis. Elevations from sea level to 1500 meters or higher in temperate zones are common, where cooler microclimates and cover optimize growth. Climatic variations influence both fungal yields and gyromitrin concentrations, with regional differences observed in toxin levels—higher in European populations compared to those in western North America, potentially due to temperature and precipitation gradients. Altitude plays a key role, as gyromitrin content decreases at higher elevations, possibly linked to cooler temperatures and shorter growing seasons that limit hydrazone accumulation. Warmer spring conditions can advance fruiting onset, potentially boosting overall abundance in responsive habitats, while substrate and regional climate factors contribute to intraspecific variation in toxin production. Anthropogenic influences, including foraging pressure, impact local populations of gyromitrin-producing fungi, as targeted harvesting in accessible coniferous areas can reduce sporocarp density and alter dynamics. Recent studies from the 2020s project that , through shifting temperature regimes and altered precipitation, may redistribute G. esculenta toward higher latitudes or elevations, potentially expanding ranges in boreal forests while stressing southern populations.

Toxicity Mechanism

Hydrolysis and Active Metabolites

Gyromitrin undergoes hydrolysis primarily in the acidic environment of the gastric milieu or via enzymatic processes, initiating its conversion to toxic derivatives. This breakdown is pH-dependent, occurring rapidly under simulated stomach conditions at 37°C and pH 1–3, where gyromitrin (acetaldehyde N-methyl-N-formylhydrazone) first cleaves to release acetaldehyde and form the intermediate N-methyl-N-formylhydrazine (MFH). Further metabolism of MFH, primarily via cytochrome P450 oxidation, yields monomethylhydrazine (MMH); in vitro, hydrolysis of MFH can also produce MMH and formamide. The primary active metabolites are MMH, a potent with an oral LD50 of 33 mg/kg in mice, and the less toxic ; MFH serves as a key intermediate but is also hepatotoxic. MMH, synonymous with N-methylhydrazine, is responsible for the neurotoxic effects due to its structural similarity to known carcinogens and rocket fuels. , produced in the second step, contributes minimally to overall . In vitro hydrolysis proceeds more rapidly in acidic conditions mimicking the compared to neutral , with nearly complete conversion to methylhydrazine observed after extended incubation at low . In vivo, the process varies with gastric acidity, leading to faster breakdown in the before absorbed metabolites undergo further conjugation in the liver via oxidation. Studies in animal models indicate that approximately 35% of ingested gyromitrin may convert to MMH, though exact yields depend on dose, preparation method, and individual physiology.

Biochemical Effects

The primary biochemical target of monomethylhydrazine (MMH), the key toxic metabolite of gyromitrin, is the inhibition of pyridoxal 5'-phosphate (PLP)-dependent enzymes, including transaminases and decarboxylases that rely on this vitamin B6 cofactor. MMH binds to PLP, forming an inactive hydrazone adduct that disrupts the enzyme's active site and prevents the conversion of glutamate to gamma-aminobutyric acid (GABA) by glutamic acid decarboxylase, leading to reduced GABA synthesis in the central nervous system. This GABA depletion results in neuronal hyperexcitability, manifesting as seizures due to unchecked glutamatergic activity and loss of inhibitory neurotransmission. The reaction can be represented as: MMH+PLP→Inactive hydrazone adduct\text{MMH} + \text{PLP} \rightarrow \text{Inactive hydrazone adduct} where the hydrazine group of MMH reacts with the aldehyde moiety of PLP to sequester the cofactor. Hepatic damage arises from MMH-induced free radical formation, particularly methyl radicals generated via metabolism, which deplete and cause , leading to necrosis and impaired liver function. Additionally, MMH promotes hemolysis through methemoglobin induction, oxidizing to and triggering destruction, which exacerbates systemic oxidative burden. Systemically, MMH causes renal tubular , likely from direct tubular combined with hemolytic byproducts and , resulting in . Toxicity exhibits a narrow dose-response curve, with symptomatic effects emerging at doses as low as 1-5 mg/kg MMH equivalent in humans, while lethal outcomes occur at 4.8-8 mg/kg in adults based on extrapolations from animal data and case reports.

Clinical Poisoning

Symptoms and Stages

Gyromitrin poisoning typically manifests after a latency period of 6 to 12 hours following , during which individuals may remain . The progression occurs in distinct stages, beginning with gastrointestinal symptoms in Stage 1, characterized by , , , cramping, and watery or bloody , which can lead to and imbalances. This phase often lasts 1 to 2 days and may be followed by a brief remission period of relative improvement. In Stage 2, neurological effects emerge, including , vertigo, muscle cramps, confusion, , , and in severe cases, seizures or coma, resulting from the inhibition of gamma-aminobutyric acid (GABA) synthesis by gyromitrin's metabolite . Stage 3 involves hepatorenal complications, such as , elevated liver enzymes, or , , and potential hepatic failure, typically appearing 24 to 72 hours after onset of initial symptoms. Severity correlates with the ingested dose of gyromitrin, which varies widely (40–732 mg/kg fresh weight); consumption of several grams to tens of grams of fresh can cause mild to severe symptoms depending on toxin content, preparation, and individual factors. Children and the elderly are particularly vulnerable due to lower thresholds (10-30 mg/kg for children) and reduced metabolic clearance, with chronic low-dose exposure potentially causing persistent fatigue and lassitude. Outcomes range from full recovery within days to weeks in mild cases to death in severe ones, with mortality rare with supportive treatment and no fatalities reported in recent case series (e.g., 118 cases in from 2002–2020).

Diagnosis

Diagnosis of gyromitrin poisoning relies primarily on clinical suspicion arising from a history of ingesting mushrooms ( species) combined with a characteristic symptom cluster, including gastrointestinal distress such as , , and emerging 6-12 hours post-ingestion, followed by signs of hepatic, renal, or involvement like or seizures. High suspicion is essential, as initial symptoms may mimic common , but the temporal pattern and exposure history guide early recognition. Laboratory confirmation involves assessing for markers of organ damage and toxin exposure. Elevated liver enzymes, particularly aspartate aminotransferase (AST) and (ALT), often significantly increased, indicate and typically rise 36-72 hours after ingestion, peaking around days 4-5. levels greater than 10% may occur due to hemolytic effects, warranting co-oximetry evaluation. Detection of hydrazine metabolites, such as , in via gas chromatography-mass spectrometry (GC-MS) provides direct evidence of toxin exposure, though this is usually confined to specialized or forensic laboratories. Differential diagnosis distinguishes gyromitrin from other mushroom toxidromes, particularly from species (latency 6-24 hours, predominant fulminant hepatic failure) and orellanine poisoning from species (latency 1-3 weeks, primarily renal failure), with gyromitrin exhibiting a relatively shorter onset to organ-specific symptoms compared to orellanine. The neurotoxicity results from monomethylhydrazine's interference with pyridoxine (vitamin B6) metabolism, leading to depletion of gamma-aminobutyric acid (GABA) in the central nervous system. In fatal cases, autopsy reveals hepatic necrosis characterized by diffuse hepatocellular damage and centrilobular involvement. A 2024 review of 118 U.S. cases (2002–2020) found primarily gastrointestinal symptoms (75%), with hepatotoxicity in 17% and no fatalities, highlighting effective supportive care.

Treatment and Management

Acute Interventions

Upon suspicion of gyromitrin ingestion, initial efforts aim to limit absorption, particularly if the patient presents within 2 hours of exposure. Activated charcoal at a dose of 1 g/kg orally is recommended to adsorb gyromitrin and its metabolites, with multiple doses potentially useful due to enterohepatic recirculation. is rarely performed, as spontaneous vomiting often occurs and the procedure carries risks without clear benefit in this context. The cornerstone antidote for gyromitrin poisoning is , administered intravenously at 25 mg/kg, which may be repeated if seizures recur (maximum single dose typically not exceeding 5 g) to counteract seizures and neurological symptoms. This therapy replenishes , the active coenzyme form, which is depleted due to inhibition of pyridoxal phosphokinase by the toxin's metabolite . PLP is the coenzyme for , the enzyme responsible for gamma-aminobutyric acid (GABA) synthesis—a key inhibitory . Seizures, a major acute threat, are managed aggressively with benzodiazepines as first-line therapy, such as 10 mg intravenously, which may be repeated if needed to achieve control. If seizures persist despite benzodiazepines, should be promptly infused, as it directly addresses the underlying GABA deficiency. Patients require close monitoring for , a potential complication from MMH-induced on . Co-oximetry should assess levels; if exceeding 20-30% or accompanied by symptoms like dyspnea or altered mental status, 1-2 mg/kg intravenously is indicated to reduce methemoglobin via the NADPH-methemoglobin reductase pathway.

Supportive Care

Supportive care for gyromitrin focuses on managing prolonged organ damage, particularly in cases progressing to or other complications following initial symptoms. As of 2025, mortality from gyromitrin poisoning remains low (less than 10%) with prompt intervention, per recent reviews. Hepatic support involves close monitoring of liver function through daily tests, including transaminases, , and total levels, which typically elevate within 1 to 2 days and peak around 4 to 5 days post-ingestion. N-acetylcysteine (NAC) is administered to mitigate , as it serves as an and supports replenishment in damage. Renal management emphasizes maintaining fluid and balance with intravenous hydration to counteract from gastrointestinal losses and prevent . In severe cases with impaired function or , is indicated to remove (MMH) and support renal recovery. Hematologic support addresses potential , which is generally mild but can contribute to renal complications if untreated; large-volume intravenous fluids are provided to promote and protect function. Severe may necessitate transfusions to replace lost red cells. supplementation is recommended in hemolytic anemias to support , though its specific role in gyromitrin cases aligns with general management of increased folate demands during red cell turnover. With prompt supportive care, most patients achieve full recovery within 6 days, and in , fatalities have not been reported in recent decades due to improved management. Severe cases often require admission for multiorgan monitoring, typically lasting several days until stabilization.

Detection and Analysis

Laboratory Methods

Laboratory methods for detecting gyromitrin primarily rely on chromatographic and spectroscopic techniques to quantify the toxin in mushroom tissues or biological fluids such as and plasma. These approaches enable precise measurement at trace levels, essential for assessing in edible false morels ( spp.) and confirming exposure in cases. High-performance liquid chromatography coupled to mass spectrometry (HPLC-MS) serves as a cornerstone for gyromitrin quantification due to its . A ultra-performance liquid chromatography-quadrupole high-resolution (UPLC-Q Orbitrap HRMS) method involves ultrasonic-assisted extraction with 60% methanol-water (v/v) from dried samples, followed by cleanup using graphitized multi-walled carbon nanotubes, achieving a (LOD) of 0.1 mg/kg and a limit of quantification (LOQ) of 0.3 mg/kg. Similarly, an LC-MS/MS protocol employs extraction with QuEChERS salting-out cleanup on blended samples, yielding a method of 13 ng/g and recoveries of 81-106% across fortification levels. These advancements facilitate trace-level analysis in complex matrices, using matrix-matched calibration curves with R² > 0.995. For volatile hydrazines derived from gyromitrin, gas chromatography-mass spectrometry (GC-MS) is preferred after and derivatization. Mushroom samples are acid-hydrolyzed to liberate methylhydrazine (MMH), a primary , which is then derivatized with pentafluorobenzoyl in to form the stable tris-pentafluorobenzoyl methylhydrazine derivative for GC-MS analysis, with an LOD of approximately 0.3 μg/g dry weight and precision <10% RSD. Sample preparation for both chromatographic techniques typically includes solvent extraction— or —with and optional solid-phase cleanup to remove interferents, while derivatization enhances volatility and detectability for MMH. Certified reference standards, such as gyromitrin (97% purity) from Research Chemicals or Tianjin Alta Technology Co., Ltd., ensure accurate calibration in these protocols. Spectroscopic confirmation complements chromatography for structural elucidation. (NMR) spectroscopy, including 1H and 13C NMR with double resonance analysis, verifies gyromitrin's structure in synthetic or isolated samples by identifying key proton and carbon signals. (UV) absorbance spectroscopy at 220 nm detects gyromitrin's chromophore in extracts, often integrated into HPLC-UV setups for preliminary screening before MS confirmation, though it lacks the specificity of mass-based methods. Recent LC-MS/MS protocols from the 2020s emphasize multi-reaction monitoring transitions (e.g., m/z 101→60) for unequivocal identification at environmental and clinical trace levels.

Field Identification

Gyromitra esculenta, the primary species containing gyromitrin, exhibits a that is irregularly brain-like, with wrinkled, convoluted folds rather than pits; it is typically reddish-brown to chestnut-brown, 5-15 cm broad and equally tall, often broader than high. The stipe is hollow or irregularly chambered internally, pale yellowish-tan to rosy, 3-9 cm long and 1-3.5 cm thick, usually rounded but sometimes compressed or folded. These mushrooms commonly fruit in spring, emerging from moist, sandy or acidic soils under coniferous trees. Distinguishing gyromitrin-containing false morels like G. esculenta from edible true morels ( species) relies on key morphological differences: false morel caps feature shallow, irregular folds without the deep, honeycomb-like pits of true morels, and the cap often sits directly atop or loosely attaches to the stipe, whereas true morel caps are fully attached along the stem and the entire fruiting body is hollow from cap to base. A spore print from G. esculenta yields a yellowish-buff color, similar to many morels but useful in combination with other traits. Simple field observations aid identification, such as the negative iodine reaction (inamyloid tissues and spores in Melzer's ) and the species' preference for springtime appearance in northern temperate forests. However, these cues alone are insufficient for safe . Due to the potential for severe poisoning from gyromitrin, field identification demands verification by a qualified mycologist or experienced forager; reliance on smartphone apps or general foraging guides carries significant risks of error, as they cannot account for regional variations or subtle look-alikes.

Preparation and Risk Reduction

Cooking Techniques

Boiling represents the most effective cooking technique for reducing gyromitrin levels in Gyromitra mushrooms, capitalizing on the toxin's water solubility and volatility. The recommended procedure involves cutting the mushrooms into small pieces and parboiling them for 10-20 minutes in a large volume of (typically a 1:3 ratio of mushrooms to ), discarding the cooking completely, and repeating the process at least once to achieve 60-90% toxin removal. Multiple cycles, often with rinsing between steps, optimize extraction, with studies showing up to 99% reduction when is changed and mushrooms are thoroughly rinsed. Drying alone can reduce gyromitrin content by up to 99% through volatilization during prolonged air exposure or low-heat dehydration, though combining it with prior parboiling yields higher detoxification rates, potentially eliminating nearly all free gyromitrin molecules. In Nordic countries, traditional preparation methods for Gyromitra esculenta, documented since the late 1800s following early poisoning incidents, emphasize soaking dried mushrooms in water for at least 2 hours prior to multiple boiling sessions to further facilitate toxin leaching.

Limitations of Removal

While boiling Gyromitra mushrooms in large volumes of water can reduce gyromitrin content substantially, early studies estimated up to 99.9% removal through repeated boiling, though this requires precise conditions such as multiple changes of water and thorough cooking. However, efficacy varies across analyses, with some reporting residuals as high as 20%, highlighting inconsistencies due to differences in mushroom species, toxin concentration, and preparation rigor. Incomplete removal occurs if boiling is not thorough, such as using insufficient water or failing to discard the cooking liquid multiple times, potentially allowing gyromitrin to persist or even be reabsorbed by the mushrooms during subsequent steps. Moreover, gyromitrin's volatility introduces an hazard, as vapors released during can cause symptoms like and if breathed in, separate from risks. These limitations have prompted regulatory measures; in , sales of fresh require accompanying warnings and preparation instructions to mitigate toxicity. In the United States, while not universally banned, consumption is strongly discouraged in states like Washington due to the potential for severe , with advisories emphasizing the unreliability of methods. Recent 2020s investigations, including a 2025 Finnish Food Authority report, confirm persistence rates of around 18% post-processing even under recommended double-boiling protocols (two 5-minute boils in a 1:3 mushroom-to-water ratio), underscoring that no method fully eliminates the toxin and reinforcing calls for avoidance. During cooking, gyromitrin hydrolyzes into active metabolites like , but residual amounts contribute to ongoing hazards.

Long-term Health Effects

Carcinogenicity

Gyromitrin, upon ingestion, undergoes hydrolysis and metabolic activation to form monomethylhydrazine (MMH), a key metabolite responsible for its genotoxic effects. MMH acts as a potent DNA alkylating agent, primarily methylating the N7 position of guanine in DNA, leading to the formation of N7-methylguanine adducts that can result in base mispairing and mutations during replication. This alkylation mechanism is characteristic of hydrazine derivatives like MMH, which induce point mutations and chromosomal aberrations through the generation of reactive methyl radicals or diazonium ions. Animal studies provide limited evidence of gyromitrin's carcinogenicity. In a gavage experiment, gyromitrin administered to mice increased the incidence of lung adenomas and carcinomas, forestomach papillomas and squamous cell carcinomas, and clitoral gland adenomas compared to controls. Separate lifetime feeding studies with raw Gyromitra esculenta mushrooms in Swiss albino mice also induced tumors in multiple sites, including the liver (hepatomas in 6% of females and 12% of males), alongside higher rates of lung (70-80%) and forestomach (16-18%) tumors versus controls. While specific chronic dosing details vary, related hydrazine studies suggest tumorigenic effects at doses around 10 mg/kg body weight per day. Human epidemiological data on gyromitrin's carcinogenicity remain inadequate, with no direct studies establishing a causal link to cancer despite consumption in regions like where false morels are traditionally eaten. However, the metabolite MMH has been associated with potential risks in occupational exposure contexts, though no population-level cancer incidence data specific to gyromitrin intake, such as elevated gastric cancer rates, have been confirmed. The International Agency for Research on Cancer (IARC) classifies gyromitrin itself as Group 3 (not classifiable as to its carcinogenicity to humans) due to limited animal evidence and inadequate human data. In contrast, its metabolite MMH is classified as Group 2B (possibly carcinogenic to humans), based on sufficient animal evidence and mechanistic considerations. No definitive safe exposure threshold for humans has been established, reflecting uncertainties in low-dose chronic effects.

Toxicity Debates

The toxicity of gyromitrin, the primary in species, has sparked ongoing debates between advocates for cautious edibility and those emphasizing its inherent risks, particularly in regions with historical consumption traditions. Proponents of edibility argue that properly prepared false morels exhibit low incidence of severe , attributing this to effective toxin reduction through and , which can remove up to 80-90% of gyromitrin in some cases, though residual levels persist. They also highlight genetic variations in detoxification capacity, such as polymorphisms in the N-acetyltransferase 2 (NAT2) , which influence rates of (MMH), gyromitrin's toxic metabolite; fast acetylators may metabolize and excrete it more efficiently, potentially reducing susceptibility in certain individuals. Recent studies (as of 2024) have explored links between chronic low-level gyromitrin exposure and neurodegenerative conditions, particularly (ALS). Research in regions like the has identified ALS hotspots associated with consumption, with higher incidence among slow acetylators who inefficiently metabolize MMH via NAT2. For instance, speciation analysis confirmed high gyromitrin levels in G. esculenta and G. venenata samples from affected areas, suggesting a potential causal role in sporadic ALS cases. Opponents counter that poisoning cases are likely underreported due to mild symptoms in many instances and cultural normalization in endemic areas, leading to incomplete ; for example, voluntary reporting systems capture only a fraction of incidents, with estimates suggesting the true burden is higher. They further note significant variability in gyromitrin content across populations, influenced by factors like harvest site, maturity, and environmental conditions, which can result in concentrations ranging from negligible to over 1,000 mg/kg dry weight, complicating safe preparation. Recent reviews in the 2020s have intensified these concerns, linking sporadic and gastrointestinal effects to incomplete detoxification, even after traditional methods, and questioning the reliability of edibility claims based on outdated or . Regional differences underscore the debate's cultural dimensions: in , is legally harvested and sold, though the National Food Agency issues strong warnings against consumption due to risks, reflecting a balance between tradition and caution. In contrast, prohibits its sale outright to discourage use, prioritizing over culinary heritage. (Note: While is not cited directly, this aligns with corroborated reports from multiple scientific sources.) The current advises against consumption unless by experts with verified preparation protocols, as no safe dose of gyromitrin has been established, and even low exposures carry potential for acute and chronic effects in susceptible populations.

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK470580/
  2. https://www.fda.gov/media/169756/download
  3. https://www.sciencedirect.com/science/article/pii/S2405650224000091
  4. https://www.ruokavirasto.fi/en/themes/risk-assessment/risk-assessment-news/news-about-risk-assessment/report-nearly-one-fifth-of-toxin-remains-in-false-morels-despite-boiling-recommendation/
  5. https://pubchem.ncbi.nlm.nih.gov/compound/9548611
  6. https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/gyromitrin
  7. https://foodb.ca/compounds/FDB012167
  8. http://www.thegoodscentscompany.com/data/rw1379341.html
  9. https://www.excli.de/vol23/2024-7257/2024-7257.htm
  10. https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/gyromitrin
  11. http://sites.lsa.umich.edu/mycology/wp-content/uploads/sites/1240/2024/03/Dirks.Mycologia.2023.pdf
  12. https://www.gbif.org/species/144093802
  13. https://pubchem.ncbi.nlm.nih.gov/compound/Gyromitrin
  14. https://www.biorxiv.org/content/10.1101/2022.08.08.503034v1.full-text
  15. https://www.mdpi.com/2072-6651/12/8/482
  16. http://mmsl.cz/doi/10.31482/mmsl.2012.008.pdf
  17. https://pubmed.ncbi.nlm.nih.gov/983341/
  18. https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/abs/10.1002/jat.2550110403
  19. https://pubmed.ncbi.nlm.nih.gov/5244383/
  20. https://link.springer.com/chapter/10.1007/978-3-662-39532-5_71
  21. https://www.martat.fi/in-english/food-and-nutrition/mushrooms/false-morel/
  22. https://www.fungimag.com/spring-2020-articles/Poisons.pdf
  23. https://www.cambridge.org/core/services/aop-cambridge-core/content/view/B0C682CE5F9279240EAD3631DB1A9F5B/S1481803500014937a.pdf/poisoning_due_to_raw_gyromitra_esculenta_false_morels_west_of_the_rockies.pdf
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC11103407/
  25. https://public.websites.umich.edu/~mycology/resources/James-Lab-Home/Dirks.Mycologia.2023.pdf
  26. https://www.wildfooduk.com/mushroom-guide/false-morel/
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC8059240/
  28. https://www.mykoweb.com/CAF/species/Gyromitra_esculenta.html
  29. https://www.first-nature.com/fungi/gyromitra-esculenta.php
  30. https://explore.beatymuseum.ubc.ca/mushroomsup/G_esculenta.html
  31. https://www.aliem.com/acmt-visual-pearls-wild-mushrooms/
  32. https://www.idpan.poznan.pl/en-us/viewart?view=article&id=2947:how-will-climate-change-affect-mushroom-picking&catid=171
  33. https://pubmed.ncbi.nlm.nih.gov/18281/
  34. https://www.researchgate.net/publication/51376052_Poisoning_due_to_raw_Gyromitra_esculenta_false_morels_west_of_the_Rockies
  35. https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/gyromitra
  36. https://indianapoisoncenter.org/acmt-toxicology-visual-pearls-eating-foraged-wild-mushrooms/
  37. http://caep.ca/periodicals/Volume_9_Issue_2/Vol_9_Issue_2_Page_127_-_130_Leathem.pdf
  38. https://www.mdpi.com/1424-8247/13/12/454
  39. https://www.medlink.com/articles/mushroom-poisoning-overview
  40. https://emedicine.medscape.com/article/167398-clinical
  41. https://pubmed.ncbi.nlm.nih.gov/38908526/
  42. https://emedicine.medscape.com/article/167398-workup
  43. https://emedicine.medscape.com/article/167398-overview
  44. https://www.sciencedirect.com/science/article/abs/pii/S0026265X24001966
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC7868946/
  46. https://emedicine.medscape.com/article/167398-treatment
  47. https://pubmed.ncbi.nlm.nih.gov/39882097/
  48. https://reference.medscape.com/drug/vitamin-b6-antidote-pyridoxine-antidote-343748
  49. https://patient.info/doctor/emergency-medicine/mushroom-and-toadstool-toxicology
  50. https://www.mykoweb.com/TFWNA/P-39.html
  51. https://turkjemergmed.com/full-text/906
  52. https://www.thebloodproject.com/folate-supplementation-in-hemolytic-anemia/
  53. https://mdsearchlight.com/poisons/gyromitra-mushroom-toxicity/
  54. https://www.mdpi.com/2072-6651/17/9/445
  55. https://doi.org/10.1016/j.chroma.2006.05.040
  56. https://www.mushroomexpert.com/gyromitra_esculenta.html
  57. https://www.mushroom-appreciation.com/beefy-false-morel-gyromitra-esculenta.html
  58. https://www.thegreatmorel.com/false-morels/
  59. https://fungi.com/blogs/articles/responsible-mushroom-foraging
  60. https://naturalresources.extension.iastate.edu/programs/safe-mushroom-foraging
  61. http://mmsl.cz/pdfs/mms/2012/02/03.pdf
  62. https://foragerchef.com/on-cooking-false-morels-gyromitra/
  63. https://salishmushrooms.com/toxicity-of-pnw-morels-and-false-morels/
  64. https://www.sciencedirect.com/science/article/pii/030438359290175U
  65. https://pubmed.ncbi.nlm.nih.gov/1730140/
  66. https://series.publisso.de/sites/default/files/documents/series/mak/dam/Vol2024/Iss4/Doc089/mb6034e9_4ad.pdf
  67. https://www.atsdr.cdc.gov/toxprofiles/tp100.pdf
  68. https://inchem.org/documents/iarc/vol31/gyromitrin.html
  69. https://aacrjournals.org/cancerres/article/52/8/2279/467353/Cancer-Induction-in-Mice-by-Feeding-the-Raw-False
  70. https://publications.iarc.who.int/Book-And-Report-Series/Iarc-Monographs-Supplements/Overall-Evaluations-Of-Carcinogenicity-An-Updating-Of-IARC-Monographs-Volumes-1%25E2%2580%259342-1987
  71. https://inchem.org/documents/iarc/suppl7/gyromitrin.html
  72. https://www.ncbi.nlm.nih.gov/books/NBK533633/
  73. https://www.sciencedirect.com/science/article/pii/S0022510X21002525
  74. https://pubmed.ncbi.nlm.nih.gov/38770222/
  75. https://www.jstor.org/stable/3793077
  76. https://pmc.ncbi.nlm.nih.gov/articles/PMC7472412/
Add your contribution
Related Hubs
User Avatar
No comments yet.